1856 results about "Gut flora" patented technology

The invention discloses an intestinal flora and obesity personalized diagnosis method based on a graph attention network, and relates to the technical field of obesity diagnosis, and the method comprises the following steps: collecting gene data, building a graph structure-based model for the data to predict obesity risk and provide personalized health suggestions, each piece of microbiome data is expressed as a weighted undirected graph, a microbiome graph is constructed, the association strength between microbiome groups is calculated, and the microbiome data is expressed as a graph structure. According to the method, the graph structure model considering the relevance between the microbiome groups is constructed, the self-adaptive graph convolutional network and the heterogeneous graph attention network are utilized, multi-modal information interaction between the microbiome and clinical data is deeply mined, the processing capacity of high-dimensional and complex microbiome data is improved, and the multi-modal information interaction between the microbiome and clinical data is improved. The accurate prediction of obesity risks and the provision of personalized health suggestions are realized, the prediction accuracy and generalization ability of the model are significantly improved, and a more effective personalized obesity diagnosis effect is achieved.

The invention relates to the technical field of health management, in particular to a gastrointestinal health assessment and management method based on big data, and the method comprises the following steps: S1, health data collection: collecting multi-dimensional health data of a user; s2, data preprocessing: preprocessing the collected multi-dimensional health data; s3, regulating and analyzing intestinal microecology, namely classifying and analyzing intestinal flora based on the intestinal flora gene sequencing data of the user in combination with living habits and diet data, identifying the condition of flora imbalance, and dynamically regulating flora balance through personalized regulation suggestions; s4, gastrointestinal health state evaluation: comprehensively evaluating the gastrointestinal health state of the user; and S5, generating a personalized health management scheme: generating the personalized health management scheme. According to the invention, by monitoring the health feedback of the user in real time, the scheme can be dynamically adjusted, so that the intervention is more flexible and targeted.

The invention discloses bifidobacterium animalis subsp. Lactis for relieving ulcerative colitis and constipation and application of the bifidobacterium animalis subsp. Lactis, and belongs to the field of microorganisms. According to the invention, a strain of bifidobacterium anaticum subsp. Lactis LIHUO 01 is screened out, the strain is preserved in the Guangdong Microbial Culture Collection Center on November 20, 2024, and the preservation number is GDMCC No: 65512. The invention also discloses a preparation method of the bifidobacterium anaticum subsp. Lactis strain, and the bifidobacterium anaticum subsp. Lactis strain has the advantages that the bifidobacterium anaticum subsp. Lactis strain can be used for preparing the bifidobacterium anaticum subsp. Lactis strain; the bifidobacterium animalis subsp. Lactis LIHUO 01 has good in-vitro probiotic characteristics, has the effects of relieving ulcerative colitis, improving constipation and regulating intestinal flora, and has a good application prospect in preparation of food or health care products or medicines for relieving ulcerative colitis or improving constipation or regulating intestinal flora.

The invention relates to application of breast milk oligosaccharides to improvement of intestinal flora of mothers and infants, in particular to application of 2 '-fucosyllactose to preparation of food which is taken by a mother and contributes to regulation of intestinal flora of the mother and offspring thereof, and the mother is in a gestation period and / or a lactation period. The invention is provided through a large amount of research; when a mother supplements a certain amount of 2 '-fucosyllactose in a gestation period and / or a lactation period, the abundance of beneficial bacteria in intestinal tracts of the mother can be remarkably improved, the content of harmful bacteria is reduced, meanwhile, the abundance of beneficial bacteria in intestinal tracts of filial generations of the mother is remarkably improved, and the content of harmful bacteria is reduced; particularly, the abundance of some beneficial bacteria which cannot be directly eaten in the intestinal tracts of the mother and the offspring can be adjusted.

The invention relates to the technical field of medical informatics, and discloses an intestinal flora associated disease risk prediction system based on multi-data set difference mutual identification, and the system comprises the steps: capturing the dynamic evolution characteristics of a network through constructing a species-genus-phylum three-level microbial interaction network, and employing a time sequence diagram convolution network; and designing a network disturbance experiment, introducing a network recovery force index to quantify the network recovery capability, constructing a network vulnerability map to identify key nodes and analyze a disturbance propagation path, and integrating stable and consistent network toughness characteristics in multiple data sets to establish an early warning mechanism. By means of the method, early and accurate early warning of disease risks is achieved, and a key time window is provided for clinical intervention.

The invention relates to a weight-losing enzyme and a preparation method thereof, and belongs to the technical field of biology, and the weight-losing enzyme comprises a fruit enzyme, a vegetable enzyme, a seed enzyme and a lotus leaf extract; the fruit enzyme is obtained by performing enzymolysis on mixed fruit pulp of apples, lemons, grapefruits and haws through pectinase, performing enzymolysis through pepsase and performing co-fermentation through bifidobacterium longum and lactobacillus acidophilus; the vegetable enzyme is obtained by performing enzymolysis on mixed vegetable pulp of wax gourd pulp, celery and spinach through pectinase, performing enzymolysis through pepsin and performing fermentation through lactobacillus plantarum and bifidobacterium adolescentis; the seed enzyme is obtained by carrying out trypsin enzymolysis on mixed powder of semen raphani and phaseolus calcaratus, then carrying out nattokinase enzymolysis and then fermenting with bifidobacterium breve; the lotus leaf extract is obtained by sequentially carrying out enzymolysis on lotus leaves through hemicellulase, snail protease and nattokinase. All the components are matched for use, so that the weight-losing food has the effects of promoting digestion, inhibiting fat absorption, regulating intestinal flora, promoting metabolism and the like, and has a good weight-losing effect.

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention belongs to the technical field of medical data processing and artificial intelligence, and particularly relates to a cardiovascular disease risk prediction system based on multi-modal fusion, which comprises a multi-modal data acquisition and preprocessing module, a cross-modal association graph construction module, a dynamic fusion and prediction module based on a graph neural network and an interpretability analysis module. By constructing a heterogeneous graph fusing prior knowledge and data driving and utilizing a graph attention network to perform multi-level dynamic feature fusion, deep integration and interaction of multi-modal data such as genomes, iconography, clinical and intestinal flora metabolism are realized, so that the accuracy and interpretability of cardiovascular disease risk prediction are improved.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention relates to the technical field of biological information mining, in particular to a multi-omics data optimization method and system for intestinal flora matching and a medium. The method comprises the following steps: acquiring historical intestinal tract multi-omics data and integrating the historical intestinal tract multi-omics data to obtain host intestinal tract multi-omics data; performing multi-omics data fusion based on the host intestinal multi-omics data to obtain microbial flora fusion data; performing pattern classification according to the host intestinal tract multi-omics data to obtain host intestinal tract physiological pattern data; carrying out physiological pattern influence factor calculation on the microbial flora fusion data to obtain host intestinal tract physiological pattern influence factors; and performing host intestinal flora matching on the microbial flora fusion data and the host intestinal physiological data according to the host intestinal physiological pattern influence factor, thereby obtaining intestinal flora matching data. According to the method, the accuracy of flora matching prediction can be improved.

The invention relates to a method for identifying a disease microorganism-metabolite combined marker based on a host-flora co-metabolism model. The method comprises the following steps: processing microbiome data; setting diet constraint conditions; determining classification composition of intestinal microorganisms of each individual, mapping abundance of each microorganism to a human microorganism genome scale metabolism model, and constructing an individualized flora metabolism network model; carrying out metabolic flow simulation on the constructed flora metabolism network model; integrating the constructed flora metabolism network model with the host metabolism network model, and predicting the metabolic flow and metabolite change of the whole system; and establishing a disease classifier based on a random forest machine learning algorithm to identify the microorganism-metabolite combined marker. According to the method, the complex metabolic process between the human body and the intestinal flora is restored in a metabolic network modeling and metabolic flow simulation mode, the method has the non-invasive characteristic, the time and economic cost is remarkably reduced, and meanwhile, the method has a great advantage in accuracy.

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention discloses application of Lactobacillus reuteri CCFM1289 with high yield of indoleacetic acid in relieving anxiety and depression, and belongs to the technical field of microorganisms. The Lactobacillus reuteri CCFM1289 can produce heteroauxin at high yield in vivo and in vitro, promote the yield of heteroauxin in fecal flora, relieve anxiety-like and depression-like behaviors of depression mice, relieve HPA hyperfunction, improve the level of brain-derived neurotrophic factor BDNF in hippocampus, promote secretion of 5-HTP and 5-HT in brain, improve the content of heteroauxin in colon, serum and brain, and improve the content of heteroauxin in colon, serum and brain. The compound can be used for improving intestinal flora metabolism imbalance, improving mRNA levels of hippocampal neurogenin-2, synapsin and post-synaptic dense protein 95, maintaining neuronal synaptic function stability, activating AHR signal channels, improving bicortin DCX expression and promoting neurogenesis so as to relieve depression mood, and can be used for drugs, health care products or healthy food for preventing and treating depression.

The invention discloses a multi-modal animal abnormal data behavior classification method and device which are applied to the technical field of data processing, and the method comprises the steps: obtaining abnormal data of a target animal in different development stages; the abnormal data comprises behavior video data and intestinal flora data of the same animal; performing feature extraction on the behavior video data to obtain behavior features representing animal action modes; analyzing the intestinal flora data to obtain intestinal flora characteristics; performing multi-modal data fusion on the behavior characteristics and the intestinal flora characteristics to generate fusion characteristics; inputting the fusion features into a pre-trained data model, classifying animal behaviors through the data model, and outputting a classification result; through the behavior-flora multi-modal fusion strategy, the classification accuracy is improved, and clues are provided for early intervention.

The invention discloses a method and system for predicting juvenile depression based on intestinal flora, and relates to the technical field of bioinformatics and artificial intelligence, and the method comprises the steps: firstly, obtaining an original sequence of a microbiome, carrying out the preprocessing of the original sequence of the microbiome, and obtaining a feature matrix; and screening core flora characteristics with stable trans-folding by adopting characteristic importance evaluation and interpretability analysis based on a gradient boosting decision tree. A mixed weighted graph is constructed based on Spearman correlation and a proximity relationship, and an absolute value of a correlation coefficient is taken as an edge weight and an edge density is adjusted through a threshold adaptive strategy. And finally, through an improved graph attention neural network, based on edge weight attention, layer normalization and random inactivation, enhancing robustness, and adopting adaptive optimization to complete parameter learning. And determining a dynamic classification threshold according to the AUC of the target patient, and outputting a sample discrimination result and confidence. According to the method, the accuracy, stability and biological interpretability of juvenile depression recognition are remarkably improved.

The invention relates to the technical field of feed products, in particular to a fatty acid composition and application thereof in preparation of products for improving intestinal health. The fatty acid composition comprises arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, butyric acid and lauric acid, or a precursor substance capable of releasing the fatty acid in the digestive tract, and the mass of the fatty acid composition is calculated according to the mass of the arachidonic acid, the mass of the docosahexaenoic acid, the mass of the eicosapentaenoic acid, the mass of the butyric acid and the mass of the lauric acid. The additive is prepared from the following components in parts by weight: 7-10 parts of arachidonic acid, 3-7 parts of docosahexaenoic acid, 3-7 parts of eicosapentaenoic acid, 2-5 parts of butyric acid and 1-3 parts of lauric acid. The composition can effectively relieve inflammation and diarrhea, regulate intestinal flora and improve intestinal health, and drug resistance is not prone to being generated.

The invention belongs to the technical field of intestinal flora transplantation, and discloses an intestinal flora enrichment microsphere as well as a preparation method and application thereof and an enrichment method of intestinal flora. The intestinal flora enrichment microsphere provided by the invention specifically comprises a calcium alginate gel substrate and a porous adsorbent doped on the calcium alginate gel substrate, and the intestinal flora-enriched microspheres have a special pore size distribution situation, namely the pore size is gradually increased along the direction from the center to the outer layer. When the intestinal flora enrichment microspheres are applied to enrichment of intestinal flora, active flora cells can be effectively separated from small impurities such as intestinal contents and flora metabolites while the proportion of the high-activity flora cells is kept, and the intestinal flora enrichment microspheres have an excellent intestinal flora enrichment effect.

The invention belongs to the technical field of biological medicines, and particularly relates to a plant lactobacillus YYY01 strain and application thereof in anti-inflammation and production of gamma-aminobutyric acid. The preservation number of the plant lactobacillus YYY01 provided by the invention is GDMCC (China General Microbiological Culture Collection Center) NO: 65147. The plant lactobacillus YYY01 has relatively good biological safety, relatively good survival in a gastrointestinal tract environment and certain intestinal tract adhesion capacity; the plant lactobacillus YYY01 can produce gamma-aminobutyric acid at high yield, and has the effects of resisting inflammation, regulating intestinal flora and enhancing immune barrier. Good application prospects are shown in the aspects of improving the yield of gamma-aminobutyric acid and preparing products containing gamma-aminobutyric acid.

The invention discloses a bifidobacterium breve BX-18 strain, and the preservation number of the bifidobacterium breve BX-18 strain is CGMCC (China General Microbiological Culture Collection Center The invention also discloses application of the bifidobacterium breve BX-18 strain in preparation of food for improving intestinal flora homeostasis and improving symptoms of inflammatory bowel diseases. The invention can be used as a probiotic preparation, can be applied to products such as pharmaceutical compositions, foods, health-care products and food additives, and is used for regulating intestinal flora and preventing and improving intestinal diseases such as inflammatory bowel diseases. The probiotic preparation provided by the invention is used as a microecological preparation for regulating intestinal flora disorder caused by the inflammatory bowel disease, and has the characteristics of simplicity in taking, no toxic action and the like.

The invention relates to a method for screening FMT (intestinal flora transplantation) donors easy to colonize. Comprising the following steps: collecting excrement of a receptor before intestinal flora transplantation, performing full-length 16s DNA sequencing on the excrement and a donor library, calculating the abundance and satisfaction degree of the donor and the receptor, and the like. The method provided by the invention can be used for screening a donor sample library easy to colonize for the FMT and screening and matching proper donors for patients, so that the colonization of donor strains after the FMT and the effectiveness of the FMT are ensured.

According to the probiotic agent for enhancing the immunity and improving the intestinal flora and the application of the probiotic agent, five specific different types of bifidobacterium strains are compounded, potential interaction exists among the five strains, and the five strains can cooperate with one another, so that the effect of enhancing the immunity and improving the intestinal flora is achieved. The bifidobacteria has the advantages that the bifidobacteria has synergistic interaction in the aspects of promoting the growth of immune organs and increasing the total quantity and diversity of intestinal flora, the bifidobacteria is matched with basic fermentation strains for yogurt fermentation, meanwhile, the composite prebiotics are added for synergistic yogurt fermentation, the quantity of the bifidobacteria at the end of a shelf life after the yogurt fermentation is finished is still not less than 1 * 10 < 8 > CFU / mL or 1 * 10 < 8 > CFU / g, and the content of the bifidobacteria is not less than the stability of lactic acid bacteria in the yoghourt is remarkably improved, so that the number of viable bacteria which enter the intestinal tract of a human body and play roles is remarkably increased, and the yoghourt has relatively good tolerance in the intestinal tract; the prepared yoghurt is fine and smooth in texture, rich in taste and rich in fragrance; in addition, the immune decline and intestinal flora disorder caused by cyclophosphamide (CTX) can be remarkably improved, and a positive effect on immunological enhancement is achieved.

The invention relates to the technical field of microorganisms, and particularly discloses a fermentation method of bifidobacterium longum BBMN68 as well as a fermented product, a postbiotic and application of the fermented product. According to the method for fermenting the bifidobacterium longum BBMN68, a fermentation substrate comprises alkaline protease hydrolyzed milk and a pomelo peel extract; the hydrolysis rate of the alkaline protease hydrolyzed milk is 9-11%, and the water-soluble dietary fiber content of the shaddock peel extract is 75-80%; the mass ratio of the alkaline protease hydrolyzed milk to the shaddock peel extract is (10-15): (1-3). The content of active ingredients in the fermented product prepared by the method is high, and after the fermented product is prepared into the postbiotics to be taken, the immune function of an organism can be recovered, immune organ damage is reduced, inflammation is relieved, and intestinal flora is regulated and controlled.

The invention discloses an intestinal flora marker related to juvenile depression, a product and application of the intestinal flora marker. The intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of prokaryotic streptococcus parahaemolyticus, streptococcus salivarius, Alistipep and Lacnospiraceae, and the intestinal flora marker is prepared from any one or more of the prokaryotic streptococcus parahaemolyticus, the streptococcus salivarius, the Alistipep and the Lacnospiraceae, the prokaryotic streptococcus parahaemolyticus, the Streptococcus salivarius, the Alistipep and the Lacnospiraceae. The invention provides a kit which comprises a detection reagent for detecting the relative abundance of the intestinal flora marker. The invention provides a product for diagnosing juvenile depression and a computer program product related to the juvenile depression. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of depression of teenagers, and provides a new tool for clinical diagnosis.

The invention discloses a strain of lactobacillus plantarum, which is named as L.plantarum ZW1, and the preservation number of the lactobacillus plantarum is CGMCC (China General Microbiological Culture Collection Center) 26685. The lactobacillus plantarum provided by the invention is a lactic acid bacterium with relatively strong broad-spectrum inhibition capability, and after the interference of organic acid and hydrogen peroxide is eliminated and protease treatment verification is carried out, the strain is determined to have relatively strong bacteriocin production capability. Probiotic performance evaluation shows that the strain has good digestive tract fluid tolerance, and the L.plantarum CGMCC26685 has good intestinal tract probiotic characteristics, can significantly enrich mouse intestinal flora in an in-vitro intestinal flora fermentation model, increase the relative abundance of the phylum of thick-walled bacteria, reduce the relative abundance of the phylum of proteobacteria, proteusbacillus and shigella, and improve the intestinal tract fluid resistance of mice. The number of flora OTU is obviously higher than that of lactobacillus rhamnosus LGG and lactobacillus plantarum L.plantarum PL4 group which does not produce bacteriocin, and the Chao1 index, the Shannon index and the Simpson index are obviously improved compared with those of a control group. It is shown that the L.plantarum CGMCC26685 has good intestinal tract beneficial activity, and has the potential of further performance excavation and application expansion.

The invention relates to ackermania muciniphila Akk21 with hypoglycemic capacity and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides an ackermania muciniphila strain Akk21 with a blood sugar reducing capability. The preservation number of the ackermania muciniphila strain Akk21 is CCTCC (China Center for Type Culture Collection) NO: M 20242779. The invention also provides hypoglycemic drugs, functional food for promoting lead excretion, health care products and a method for preventing and treating lead / arsenic pollution based on the strain Akk21. The Ackermania muciniphila Akk21 has excellent lead and arsenic tolerance and hypoglycemic capacity, can effectively reduce the blood lipid level of mice with type II diabetes, has a remarkable reduction effect on inflammation of the whole body of the mice, and can remarkably reduce the number of harmful flora in the intestinal tract by increasing the abundance of effective flora in the intestinal tract, so that the content of the harmful flora in the intestinal tract is reduced, and the content of the harmful flora in the intestinal tract is reduced. The species diversity and abundance of intestinal flora are improved.

The invention discloses lactobacillus reuteri LR69 capable of enhancing a gastric mucosal barrier and application, a product and a method thereof, and belongs to the technical field of microorganisms. The invention provides a lactobacillus reuteri LR69, and the preservation number of the lactobacillus reuteri LR69 is CGMCC (China General Microbiological Culture Collection Center) No.33731. The lactobacillus reuteri LR69 is a lactobacillus reuteri LR69. The invention also provides application of the strain in preparation of food with an auxiliary protection function on gastric mucosa, and / or food with an intestinal flora regulating function, and / or a product for relieving gastritis, and / or food with an immunity enhancing function, and / or a bacteriostatic agent. The invention further discloses a food with an auxiliary protection function on gastric mucosa, a food with an intestinal flora regulating function, a product for relieving gastritis, a food with an immunity enhancing function, a bacteriostatic agent and an in-vitro bacteriostasis method based on the strain. The lactobacillus reuteri LR69 disclosed by the invention can effectively assist in protecting gastric mucosa, regulating intestinal flora, relieving gastritis, enhancing immunity and realizing broad-spectrum bacteriostasis.

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.

The invention discloses application of lactobacillus rhamnosus in preparation of a preparation for relieving allergic rhinitis. The invention provides application of the lactobacillus rhamnosus OF44-15Ph10T or a composition containing the lactobacillus rhamnosus OF44-15Ph10T in preparation of a product with at least one of the following functions: preventing and / or treating allergic rhinitis; the symptoms of allergic rhinitis are improved or relieved; the nasal mucosa injury caused by allergic rhinitis is repaired; intestinal pathogens are inhibited; the intestinal flora balance is regulated; the lactobacillus rhamnosus OF44-15Ph10T provided by the invention provides a new direction for treating allergic rhinitis, can be applied to the fields of food, health care products and medicines, and has a wide industrial prospect.

The invention provides allium macrostemon polysaccharide as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The method comprises the following steps: extracting and purifying small root garlic to obtain crude polysaccharides, namely AMBP 40, AMBP 60 and AMBP 80; separating to prepare a polysaccharide component AMBP60-1, and then separating to prepare the uniform polysaccharide AMBP-1a of the allium macrostemon. The AMBP-1a is mainly composed of galactose, glucose and arabinose in a molar ratio of 0.836: 0.158: 0.006, and the AMBP-1a is a neutral heteropolysaccharide. The structural characteristics of polysaccharide are related to activity, AMBP-1a can effectively improve the blood fat level of ApoE- / -atherosclerosis model mice, pharmacological activity of atherosclerosis plaques and the like, and atherosclerosis is intervened by regulating intestinal flora and short-chain fatty acid content.